1. Home
  2. BPMC
  3. BPMC News

Latest Blueprint Medicines Corporation (BPMC) News on December 22, 2024

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BPMC

PR Newswire

4 days ago

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
BPMC

PR Newswire

15 days ago

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Exploring Three High Growth Tech Stocks in the United States
BPMC

Simply Wall St.

20 days ago

Exploring Three High Growth Tech Stocks in the United States

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
BPMC

Zacks

23 days ago

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?

BPMC

MT Newswires

a month ago

Blueprint Medicines Insider Sold Shares Worth $1,869,658, According to a Recent SEC Filing

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
BPMC

Benzinga

a month ago

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

BPMC

MT Newswires

a month ago

JPMorgan Initiates Blueprint Medicines at Overweight With $126 Price Target

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report
BPMC

Simply Wall St.

2 months ago

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report

High Growth Tech Stocks to Watch in November 2024
BPMC

Simply Wall St.

2 months ago

High Growth Tech Stocks to Watch in November 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations
BPMC

Simply Wall St.

2 months ago

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
BPMC

Zacks

2 months ago

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...
BPMC

GuruFocus.com

2 months ago

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...

BPMC

Thomson Reuters StreetEvents

2 months ago

Q3 2024 Blueprint Medicines Corp Earnings Call

BPMC

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Blueprint Medicines to $135 From $129, Maintains Outperform Rating

BPMC

MT Newswires

2 months ago

Blueprint Medicines Q3 Loss Narrows, Revenue Increases; 2024 Product Sales Guidance Lifted

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
BPMC

Zacks

2 months ago

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

BPMC

Associated Press Finance

2 months ago

Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
BPMC

PR Newswire

2 months ago

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic?
BPMC

Simply Wall St.

2 months ago

Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic?

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
BPMC

Zacks

2 months ago

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

BPMC

MT Newswires

2 months ago

UBS Initiates Blueprint Medicines at Neutral With $88 Price Target

Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
BPMC

Zacks

2 months ago

Regeneron (REGN) Earnings Expected to Grow: Should You Buy?

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BPMC

Zacks

2 months ago

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
BPMC

Zacks

2 months ago

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
BPMC

PR Newswire

2 months ago

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know
BPMC

Zacks

2 months ago

Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know

BPMC

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 10/07/2024

BPMC

MT Newswires

3 months ago

Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
BPMC

Zacks

3 months ago

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?

High Growth Tech Stocks To Watch In September 2024
BPMC

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In September 2024

Blueprint Medicines to Present at Upcoming Investor Conferences
BPMC

PR Newswire

3 months ago

Blueprint Medicines to Present at Upcoming Investor Conferences

Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
BPMC

Zacks

4 months ago

Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?

Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)
BPMC

GuruFocus.com

4 months ago

Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)

Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
BPMC

Zacks

4 months ago

Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

BPMC

MT Newswires

4 months ago

Blueprint Medicines Insider Sold Shares Worth $3,905,872, According to a Recent SEC Filing

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up
BPMC

Zacks

4 months ago

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up

Analysts Just Shipped A Sizeable Upgrade To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
BPMC

Simply Wall St.

4 months ago

Analysts Just Shipped A Sizeable Upgrade To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines Second Quarter 2024 Earnings: Beats Expectations
BPMC

Simply Wall St.

5 months ago

Blueprint Medicines Second Quarter 2024 Earnings: Beats Expectations

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
BPMC

Zacks

5 months ago

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat

BPMC

MT Newswires

5 months ago

Wedbush Adjusts Blueprint Medicines' Price Target to $129 From $120, Keeps Outperform Rating

BPMC

MT Newswires

5 months ago

Blueprint Medicines Q2 Loss Narrows, Revenue Rises

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
BPMC

Zacks

5 months ago

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

BPMC

Associated Press Finance

5 months ago

Blueprint Medicines: Q2 Earnings Snapshot

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
BPMC

PR Newswire

5 months ago

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
BPMC

Zacks

5 months ago

Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
BPMC

Zacks

5 months ago

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
BPMC

PR Newswire

5 months ago

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

BPMC

MT Newswires

5 months ago

Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating

BPMC

MT Newswires

6 months ago

Blueprint Medicines Insider Sold Shares Worth $7,713,537, According to a Recent SEC Filing

How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'
BPMC

Investor's Business Daily

6 months ago

How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'

Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
BPMC

GuruFocus.com

6 months ago

Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)

BPMC

MT Newswires

6 months ago

Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing

Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares
BPMC

GuruFocus.com

7 months ago

Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares

BPMC

MT Newswires

7 months ago

Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing

BPMC

MT Newswires

7 months ago

Blueprint Medicines Insider Sold Shares Worth $4,136,328, According to a Recent SEC Filing

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
BPMC

PR Newswire

7 months ago

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

BPMC

MT Newswires

7 months ago

Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
BPMC

PR Newswire

7 months ago

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year
BPMC

Simply Wall St.

7 months ago

Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year

BPMC

MT Newswires

7 months ago

Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BPMC

Zacks

8 months ago

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand

BPMC

MT Newswires

8 months ago

Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BPMC

PR Newswire

8 months ago

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BPMC

MT Newswires

8 months ago

Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating

5 Biotech Stocks Worth Adding to Your Portfolio in 2024
BPMC

Zacks

8 months ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

BPMC

MT Newswires

8 months ago

Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
BPMC

Insider Monkey

8 months ago

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
BPMC

Zacks

8 months ago

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises

BPMC

GuruFocus.com

8 months ago

Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...

BPMC

Thomson Reuters StreetEvents

8 months ago

Q1 2024 Blueprint Medicines Corp Earnings Call

BPMC

MT Newswires

8 months ago

Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating

BPMC

MT Newswires

8 months ago

Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises

BPMC

GuruFocus.com

8 months ago

Blueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ...

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
BPMC

Zacks

8 months ago

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

BPMC

Associated Press Finance

8 months ago

Blueprint Medicines: Q1 Earnings Snapshot

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
BPMC

PR Newswire

8 months ago

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
BPMC

Zacks

8 months ago

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
BPMC

Zacks

8 months ago

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
BPMC

PR Newswire

8 months ago

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
BPMC

PR Newswire

8 months ago

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BPMC

PR Newswire

9 months ago

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven?
BPMC

Simply Wall St.

9 months ago

Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven?

Insiders Are Dumping These 10 Healthcare Stocks
BPMC

Insider Monkey

9 months ago

Insiders Are Dumping These 10 Healthcare Stocks

CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
BPMC

Zacks

9 months ago

CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?

Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
BPMC

Zacks

9 months ago

Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?

30 Biggest Biotechnology Companies in the World
BPMC

Insider Monkey

9 months ago

30 Biggest Biotechnology Companies in the World

Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares
BPMC

GuruFocus.com

9 months ago

Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares

Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
BPMC

Zacks

9 months ago

Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BPMC

PR Newswire

10 months ago

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BPMC

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Rigel Pharmaceuticals Inc Earnings Call

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
BPMC

PR Newswire

10 months ago

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

Blueprint Medicines Full Year 2023 Earnings: Beats Expectations
BPMC

Simply Wall St.

10 months ago

Blueprint Medicines Full Year 2023 Earnings: Beats Expectations

Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings
BPMC

Zacks

10 months ago

Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings

Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript
BPMC

Insider Monkey

10 months ago

Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript

Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
BPMC

Zacks

10 months ago

Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines

BPMC

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Blueprint Medicines Corp Earnings Call

Blueprint Medicines Surges After Rare-Disease Drug Notches Its Fourth Quarterly Beat
BPMC

Investor's Business Daily

10 months ago

Blueprint Medicines Surges After Rare-Disease Drug Notches Its Fourth Quarterly Beat

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
BPMC

Zacks

10 months ago

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

BPMC

GuruFocus.com

10 months ago

Blueprint Medicines Corp Reports Robust AYVAKIT Revenue Growth in Q4 and Full Year 2023

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BPMC

Zacks

10 months ago

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Share on Social Networks: